Fr

Remdesivir has more than one mechanism for treating patients with COVID-19, according to new research from the U of A

The antiviral drug remdesivir inhibits the virus’ ability to replicate, researchers now say it can act as a roadblock against the spread of coronavirus in the body.
By: Heather Marie Connors
September 28, 2020
Photo by Gilead Sciences/The Associated Press

Published recently in the Journal of Biological Chemistry, University of Alberta researchers released findings that the antiviral drug remdesivir has more uses than originally thought in the fight against COVID-19. Previously established as a drug that stops the virus from replicating, the U of A research team discovered it can also prevent or delay the virus from spreading within the body.

Remdesivir currently has conditional approval from Health Canada for use in adults and adolescents with severe COVID-19 symptoms. The drug is administered intravenously and can only be used under the supervision of a healthcare provider.

"Remdesivir speeds up the time of recovery from 15 to 11 days. These randomized clinical trials, this is the gold standard to evaluate antiviral drugs," said U of A Professor Matthias Gotte, chair of medical microbiology and immunology.

Clinical trials of remdesivir are ongoing. Studies like this help doctors know how the drug can work in combination with others, and helps researchers get a better sense of how other treatments could work against COVID-19. Once a vaccine is found, treatment drugs such as remdesivir will still be important, as not everyone will be immunized right away.

Source: CBC Edmonton

Related

3 months ago

Health Canada approves use of remdesivir to treat COVID-19 patients

Antiviral medication has been shown to shorten COVID-19 recovery time by 31%.
2 months ago

Groundbreaking molecular studies in London, ON identify ways to predict the severity of illness

Two new studies out of the Lawson Health Research Institute and Western University have identified biomarkers that can predict the severity of patient illness, as well as how blood clots develop in some patients with COVID-19.